Source: Eur Respir Rev 2015; 24: 375-377



Rating:

Share or cite this content

Citations should be made in the following way:
Harari Sergio, Humbert Marc, Blasi Francesco, Collard Harold R., Matucci-Cerinic Marco, Simonneau Gerald, Vancheri Carlo, Wells Athol U., Cottin Vincent. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?. Eur Respir Rev 2015; 24: 375-377

Member's Comments

No comment yet.

Related content which might interest you: Rare pulmonary disease and orphan drugs: a path to the future Source: Eur Respir Rev, 28 (153) 190115; 10.1183/16000617.0115-2019 Year: 2019 Rare pulmonary diseases: a common fight Source: Eur Respir Rev, 26 (145) 170059; 10.1183/16000617.0059-2017 Year: 2017 What’s new in interstitial lung diseases in children? Source: Virtual Congress 2021 – Paediatric year in review Year: 2021 Bronchiectasis: how to be an orphan with many parents? Source: Eur Respir J 2016; 47: 10-13 Year: 2016 Development of medicines for rare diseases: where are the problems? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Cleaning agents: how they look like and how might they cause respiratory harm? Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health? Year: 2018 Pulmonary rehabilitation, where do we come from and where do we go to? Source: Annual Congress 2009 - PG20 State of the art in pulmonary rehabilitation Year: 2009 Chronic diseases like asthma and COPD: do they truly exist? Source: Eur Respir J 2016; 47: 359-361 Year: 2016 Sub-glottic Stenosis: An orphan tracheopathy – a great asthma mimic! Source: Virtual Congress 2021 – Comorbidities in airway obstructive diseases Year: 2021 Cleaning agents and asthma: what does the epidemiology really tell us? Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health? Year: 2018 Thrombo-embolic pulmonary hypertension: which treatment should we choose? / Hypertension pulmonaire thrombo-embolique: quel traitement choisir ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Rare and 'orphan' lung diseases Source: Breathe 2008; 5: 101-104 Year: 2008 What's it like to live with idiopathic pulmonary fibrosis? Ask the experts Source: Eur Respir J 2016; 47:1324-1326 Year: 2016 Antifungals in pulmonary infections: to whom, when and how? Source: Eur Respir Monogr 2017; 75: 159-184 Year: 2017 Treating asthma in developing countries: is this a question of money? Source: Eur Respir J 2005; 26: Suppl. 49, 274s Year: 2005 Chronic post-embolic pulmonary hypertension: a new target for medical therapies?}, Source: Eur Respir Rev 2013; 22: 258-264 Year: 2013 Toward better management of rare and orphan pulmonary diseases Source: Eur Respir J 2016; 47:1334-1335 Year: 2016 Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?}, Source: Eur Respir Rev 2013; 22: 217-226 Year: 2013 Genetic variation and common diseases. Where are we? Where to go? Source: Research Seminar 2009 - Post Genome Respiratory Epidemiology II - An interdisciplinary challenge Year: 2008